Merck KGaA raises forecasts despite drop in net income

4 August 2016
merckkgaa-big

German science and technology company Merck KGaA (MRK: DE) reported an 18.2% increase in net sales to 3.8 billion euros ($4.2 billion) in its second quarter 2016 results.

Earnings before interest, taxes, amortization and depreciation (EBITDA) pre-exceptionals, also rose sharply, by 29% to 1.2 billion euros, driven by the good operating performance of healthcare and life sciences as well as the Sigma-Aldrich acquisition. This was slightly higher than analyst estimates of 1.1 billion euros.

Earnings per share (EPS) pre-exceptionals also rose in the second quarter by 19.2% to 1.55 euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical